Crossmark

Cost implications for the NHS of using the Alere™ i Influenza A & B near patient test with nasal swabs

Crossref DOI link: https://doi.org/10.1186/s41512-018-0031-8

Published Online: 2018-08-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Allen, A. J. https://orcid.org/0000-0002-3222-0396
O’Leary, R. A.

Davis, S.

Graziadio, S.

Jones, W. S.

Simpson, A. J.

Price, D. A.

Vale, L.

Power, M.
License Information

Text and Data Mining valid from 2018-08-01
More Information

Article History

Received: 16 February 2018

Accepted: 18 May 2018

First Online: 1 August 2018

Authors’ information

: A. Joy. Allen is a Senior IVD Evaluation Methodologist with the NIHR Newcastle In Vitro Diagnostics Co-operative (NIHR Newcastle MIC). The NIHR Newcastle MIC facilitates the generation of high-quality evidence on clinical validity, utility, and cost-effectiveness of in vitro diagnostic medical devices (IVDs) for use in the NHS.

: Not applicable.

: This research has been funded by the producer of the Alere™ i Influenza A & B test. The authors declare no other competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.